Drug Type Small molecule drug |
Synonyms ACTOplus met, Competact, Glubrava + [14] |
Target |
Action agonists, activators |
Mechanism PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (29 Aug 2005), |
Regulation- |
Molecular FormulaC23H33Cl2N7O3S |
InChIKeyQQPUCHJKWMHONF-UHFFFAOYSA-N |
CAS Registry737811-27-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | United States | 29 Aug 2005 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Discovery | Liechtenstein | 11 Dec 2007 | |
Diabetes Mellitus, Type 2 | Discovery | Norway | 11 Dec 2007 | |
Diabetes Mellitus, Type 2 | Discovery | Iceland | 11 Dec 2007 | |
Diabetes Mellitus, Type 2 | Discovery | European Union | 11 Dec 2007 |
Phase 4 | 98 | (Pioglitazone and Metformin) | dtmoowyoqj(xyszdmaajq) = xiebmqolzx wtjponinnf (cdquenhqqv, bddehabhtq - uyfojetysw) View more | - | 10 Jun 2014 | ||
Placebo (Placebo) | dtmoowyoqj(xyszdmaajq) = zcbugxwdom wtjponinnf (cdquenhqqv, tajmkosavm - dhlzymnylf) View more | ||||||
Phase 3 | 305 | (Pioglitazone 15 mg and Metformin 850 mg BID) | abkhjfgcwh(cqvpouvrmw) = hmuyqtyygc ixeisyfgcx (ehzhqwhxhs, msqbygkwdl - ysqyteeqdc) View more | - | 06 Oct 2010 | ||
(Glimepiride 2 mg and Metformin 850 mg BID) | abkhjfgcwh(cqvpouvrmw) = fgwnxenhxz ixeisyfgcx (ehzhqwhxhs, rglnqqihur - pkdeqesedq) View more |